https://www.avient.com/sites/default/files/2021-03/avient-march-ir-fermium_0.pdf
Lastly, our design capabilities ensure that the application is designed perfectly for the specific end use.
Our exceptional polymer scientists and design engineers are integral to their product development process.
Design times can be less than three days for colorants.
https://www.avient.com/sites/default/files/2022-03/AVNT Mar 2022 Presentation.pdf
Lastly, our design capabilities ensure that the application is designed perfectly for the specific end use.
Our exceptional polymer scientists and design engineers are integral to their product development process.
Design times can be less than three days for colorants.
https://www.avient.com/products/polymer-additives/healthcare-additives/mevopur-healthcare-functional-additives
Designed to help you overcome challenges for healthcare devices and applications
https://www.avient.com/sites/default/files/2024-08/Avient-2023-Sustainability-Report_6.pdf
Our design recommendations help create the end use applications.
b) Facility is not included in manufacturing plants total as it is a design center/lab.
d) Location also includes a design center/lab.
https://www.avient.com/sites/default/files/2022-05/Compensation Committee Charter (REV 10-2019).pdf
General Purposes The general purposes of the Committee are to: • Develop the Company’s overall executive compensation philosophy and objectives; • Discharge the Board’s responsibilities relating to compensation of the Company’s executive officers and, further, to assist the Board in the discharge of its fiduciary responsibilities with regard to establishment of policies governing, and the implementation of, all aspects of remuneration throughout the Company, including benefits and perquisites of executive officers of the Company and any other employees designated by the Committee as key employees of the Company and its subsidiaries; • Discharge similar responsibilities with respect to the remuneration of non-employee directors; • Review and discuss with management the Company’s disclosures in the Compensation Discussion and Analysis (the “CD&A”) required by rules and regulations of the Securities and Exchange Commission (the “SEC”) and recommend to the Board whether the CD&A should be included in the Company’s proxy statement or other applicable SEC filings; • Prepare a Compensation Committee Report for inclusion in the Company’s applicable filings with the SEC that complies with the rules and regulations of the SEC; and • Provide policy guidance and oversight on significant human resource policies and practices.
Independence Assessment of Outside Advisers • The Committee may select a compensation consultant, legal counsel or other adviser to the Committee or receive advice from a compensation consultant, legal counsel or other adviser (other than in-house legal counsel or any compensation consultant, legal counsel or other adviser whose role is limited to the following activities for which no disclosure would be required under Item 407(e)(3)(iii) of Regulation S-K: consulting on any broad-based plan that does not discriminate in scope, terms, or operation, in favor of executive officers or directors of the Company, and that is available generally to all salaried employees; or providing information that either is not customized for a particular company or that is customized based on parameters that are not developed by the compensation consultant, and about which the compensation consultant does not provide advice) only after taking into consideration all factors relevant to that person’s independence from management, including the following: • the provision of other services to the Company by the employer of the compensation consultant, legal counsel or other adviser; 5 • the amount of fees received from the Company by the employer of the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of the employer of the compensation consultant, legal counsel or other adviser; • the policies and procedures of the employer of the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest; • any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the Committee; • any stock of the Company owned by the compensation consultant, legal counsel or other adviser; and • any business or personal relationship of the compensation consultant, legal counsel, other adviser or the employer of the adviser with an executive officer of the Company. • The Committee shall evaluate whether any compensation consultant retained or to be retained by it has any conflict of interest in accordance with Item 407(e)(3)(iv) of Regulation S-K.
https://www.avient.com/sites/default/files/resources/TRA%2520-%25202016%2520Plan%2520Summary.pdf
Materials or feedstock substitution, Product design or reformulation, etc.).
Materials or feedstock substitution Empty Product design or reformulation Empty Equipment or process modifications Empty Spill or leak prevention Empty Onsite reuse, recycling or recovery Empty Improved inventory management or purchasing techniques Empty Good operator practice or training About us News Contact us Stay connected HEALTH healthycanadians.gc.ca TRAVEL travel.gc.ca SERVICE CANADA servicecanada.gc.ca JOBS jobbank.gc.ca ECONOMY actionplan.gc.ca Canada.gc.ca Terms and Conditions Transparency Version: 3.13.0 Empty Identify at least one reason why no option to reduce the use or creation of this substance was implemented at your facility: Select the applicable reason or reasons ** There are no alternative processes and/or equipment identified, New equipment and/or processes were investigated, however, deemed unfeasible Explanation of the reasons why no option will be implemented Rationale for why the listed options were chosen for implementation General description of any actions undertaken by the owner and operator of the facility to reduce the use and creation of the toxic substance at the facility that are outside of the plan License Number of the toxic substance reduction planner who made recommendations in the toxic substance reduction plan for this substance (format TSRPXXXX): * TSRP0123 Name of the toxic substance reduction planner who made recommendations in the toxic substance reduction plan for this substance (First Name Last Name) Daryl Chartrand License Number of the toxic substance reduction planner who has certified the toxic substance reduction plan for this substance (format TSRPXXXX): * TSRP0123 Name of the toxic substance reduction planner who has certified the toxic substance reduction plan for this substance (First Name Last Name) Daryl Chartrand What version of the plan is this summary based on?
https://www.avient.com/products/polymer-additives/barrier-and-scavenger-additives/colormatrix-triple-acetaldehyde-scavenger-pet
Injection PET Water Bottle Company (Portuguese)
https://www.avient.com/products/polymer-additives/fiber-additives
These liquid concentrates, which are injected in the spun-dyed polymer melt, provide excellent color fastness and allow rapid color changes.
https://www.avient.com/products/polymer-additives/laser-marking-additives
Our laser marking solutions can be used in a variety of resin types and processes, including injection molding, blow molding, and extrusion.
https://www.avient.com/products/polymer-colorants/colorant-dispersions
These silicone paste colorants can be used in one-component and two-component Room Temperature Vulcanization (RTV) systems and two-part Liquid Injection Molding (LIM) systems; they provide excellent dispersion, consistent color, and a suitable viscosity for metering systems.